GlassScriptPhysician profile
Michael I Gruenebaum
NPI 1215943287
$869.30
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $281 · 2021: $31.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $251.39 | 2019-2021 | |
| Amgen INC. | $137.10 | 2019-2020 | |
| Amarin Pharma, INC. | $130.14 | 2019-2020 | |
| Novo Nordisk INC | $90.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $64.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.13 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.48 | 2019-2020 | |
| Lilly USA, LLC | $22.07 | 2019-2020 | |
| Allergan, INC. | $19.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.96 | 2020 | |
| Boston Scientific Corporation | $12.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.30 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gruenebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.